Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateWages, Salaries and Other
Others
Ratios

Sutro Biopharma (STRO) Tax Provisions (2022 - 2025)

Sutro Biopharma's Tax Provisions history spans 3 years, with the latest figure at $2.4 million for Q4 2024.

  • For Q4 2024, Tax Provisions fell 85.11% year-over-year to $2.4 million; the TTM value through Sep 2025 reached $2.4 million, down 86.62%, while the annual FY2024 figure was $2.4 million, 87.02% down from the prior year.
  • Tax Provisions for Q4 2024 was $2.4 million at Sutro Biopharma, up from $8000.0 in the prior quarter.
  • Across five years, Tax Provisions topped out at $15.8 million in Q4 2023 and bottomed at $8000.0 in Q2 2024.
  • The 3-year median for Tax Provisions is $1.8 million (2023), against an average of $3.3 million.
  • The largest YoY upside for Tax Provisions was 85.11% in 2024 against a maximum downside of 94.7% in 2024.
  • A 3-year view of Tax Provisions shows it stood at $2.5 million in 2022, then soared by 532.6% to $15.8 million in 2023, then plummeted by 85.11% to $2.4 million in 2024.
  • Per Business Quant, the three most recent readings for STRO's Tax Provisions are $2.4 million (Q4 2024), $8000.0 (Q2 2024), and $15.8 million (Q4 2023).